We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

KRAS Inhibitor Sotorasib Achieves Durable Clinical Benefit in Early Trial

News   Sep 21, 2020 | Original Source from The University Of Texas

 
KRAS Inhibitor Sotorasib Achieves Durable Clinical Benefit in Early Trial
 
 
Advertisement
 

RELATED ARTICLES

Novel Cancer Diagnostics Approach Analyzes Tumors in 3D

News

A new technique, developed at TU Wien (Vienna), together with the TU Munich, could now initiate a revolution in pathology: Tumor tissue is made transparent and illuminated with a special ultramicroscope.

READ MORE

Even After a Deep Clean, Drug-Resistant Bacteria Can Persist

News

In immunocompromised patients, Enterococcus faecium can lead to potentially life-threatening infection. A team of scientists at the University of Cambridge and the London School of Hygiene and Tropical Medicine has pioneered an approach combining epidemiological and genomic information to chart the spread of bacteria within healthcare settings.

READ MORE

Large Screen Identifies New COVID-19 Related Genes

News

Researchers at Yale University and the Broad Institute of MIT and Harvard screened hundreds of millions of cells exposed to the COVID-19 and MERS viruses and identified genes that both enable the viruses to replicate in cells and those that may prevent it.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE